Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Highly experienced ex-Delta One trader with 17 years of experience trading arbitrage and related strategies across Asian markets.

Exempt Financial Adviser (EFA) under CrossASEAN Research Pte Ltd.

It is important to note that the information provided by Periscope Analytics is based on publicly available data and own knowledge, which has been gathered and synthesized from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions.

All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include, but are not limited to, company announcements, exchange filings, ETF and other passive investment vehicle holdings, and free float and volume data from third-party data providers. Periscope Analytics does not guarantee the accuracy and completeness of the forecasts, estimates and/or other information.

Pan-Asia Index Rebalances/ Events/ Delta One

Hang Seng Biotech Index Rebalance Preview: One Set of Changes in June

Sichuan Kelun Biotech (6990 HK): Price Surge & Global Index Inclusion

Hang Seng Biotech Index Rebalance: 1 Add & 21 Deletes as Methodology Changes

Hang Seng Biotech Index Rebalance Preview: Methodology Change Leads to 20 Deletions

Hang Seng Indexes: Announcement Tomorrow; Potential Changes & Updated Flows

Hang Seng Index (HSI) Rebalance Preview: Inclusion Candidates for Sep25

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

TransThera Sciences (Nanjing) / Index Rebalance

<ul>
<li>Following the completion of the review period, there could be one set of changes for the Hang Seng Biotech Index (HSHKBIO Index) in March.</li>
<li>
<a href="https://www.smartkarma.com/entities/transthera-sciences-nanjing-inc" target="_blank" data-smartkarma-citation="entities:34404:1" rel="noopener">TransThera Sciences (Nanjing) (2617 HK)</a> could replace <a href="https://www.smartkarma.com/entities/everest-medicines-ltd" target="_blank" data-smartkarma-citation="entities:29224:1" rel="noopener">Everest Medicines (1952 HK)</a> and there will be capping changes for the largest index constituents.</li>
<li>Both stocks have dropped over the past few months as interest in the sector has cooled and some of the steam is let out. </li>
</ul>


Following the completion of the review period, there could be one set of changes for the Hang Seng Biotech Index (HSHKBIO Index) in March.

TransThera Sciences (Nanjing) (2617 HK) could replace Everest Medicines (1952 HK) and there will be capping changes for the largest index constituents.
Both stocks have dropped over the past few months as interest in the sector has cooled and some of the steam is let out. 


Hang Seng Biotech Index Rebalance Preview: One Set of Changes in March